The MELTF gene encodes melanotransferrin (MTf), a glycoprotein belonging to the transferrin family, initially identified in melanoma cells. Unlike its homolog transferrin, MTf binds iron but does not directly mediate cellular iron uptake via classical receptor pathways. Instead, it is implicated in diverse biological processes, including iron homeostasis, cell proliferation, and angiogenesis. MTf is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage but can also exist in soluble forms, detected in blood and other fluids.
MELTF antibodies are tools used to study MTf's roles in physiology and disease. Research highlights MTf overexpression in cancers (e.g., melanoma, breast, and colorectal), where it may promote tumor growth and metastasis, making it a potential therapeutic target or biomarker. Antibodies against MTf enable detection of its expression in tissues or serum, aiding in cancer diagnosis, prognosis, and mechanistic studies. Additionally, MTf’s involvement in Alzheimer’s disease (via interactions with amyloid-beta) and iron metabolism disorders has spurred interest in therapeutic antibody development.
Despite progress, MTf's precise molecular mechanisms remain unclear, necessitating further research. MELTF antibodies thus serve as critical reagents to unravel its dual roles in health and disease.